Argen-X

Research Argen-X (0QW0) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker0QW0
• ExchangeLSE
• CountryNetherlands
• SectorEnergy
• IndustryUranium
• CurrencyEUR
• Financial periodFY2025
• RevenueUSD 4.15B
• Revenue growth89.9%
• Net incomeUSD 1.29B
• Free cash flowUSD 679.03M
• Gross margin89.1%

About Argen-X

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Frequently asked questions

What does Argen-X do?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.